Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

2423studies indexed1086with human data145registered trials2091carry a numeric findingLibrarian added 0 studies today
Showing 5 studiesSortNewest indexed ▾
A
grade
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
Pemvidutide · Lancet (London, England) · 2025 · RCT · Phase 2Top journal
Pemvidutide showed a significant improvement in MASH resolution at 24 weeks compared to placebo, but did not demonstrate significant fibrosis improvement.
MASH resolution without fibrosis worsening: 58% in 1.2 mg pemvidutide group, p<0.0001.
D
grade
Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.
Pemvidutide · Naunyn-Schmiedeberg's archives of pharmacology · 2026 · Meta-analysis
Pemvidutide may significantly reduce liver fat and improve metabolic parameters in adults with MASH, but further long-term studies are needed to confirm these findings.
-52.90 MD liver fat content at 12 weeks, 95% CI -71.60 to -34.20, P < 0.00001
D
grade
Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.
Pemvidutide · Cureus · 2026 · Meta-analysis
Dual and triple GLP-1-based polyagonists may improve liver health in patients with MASLD and MASH, but gastrointestinal side effects and the need for larger studies should be noted.
RR 3.32, 95% CI 2.28-4.84; I² = 20% for MASH resolution or histological improvement without worsening of fibrosis.
Showing 5 of 5